Discovery and in Vivo Evaluation of (<i>S</i>)-<i>N</i>-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9<i>H</i>-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
Timothy D. Cushing, Xiaolin Hao, Youngsook Shin, Kristin L. Andrews, Matthew F. Brown, Mario Cardozo, Yi Chen, Jason Duquette, Ben Fisher, Felix González-López de Turiso, Xiaodong He, Kirk R. Henne, Yiling Hu, Randall W. Hungate, Michael G. Johnson, Ron C. Kelly, Brian S. Lucas, John D. McCarter, Lawrence R. McGee, Julio C. Medina, Tisha San Miguel, Deanna Mohn, Vatee Pattaropong, Liping H. Pettus, Andreas Reichelt, Robert M. Rzasa, Jennifer L. Seganish, Andrew S. Tasker, Robert C. Wahl, Sharon Wannberg, Douglas A. Whittington(Amgen (United States)), John Whoriskey, Gang Yu, Leeanne Zalameda, Dawei Zhang, Daniela Metz
Cited by 85
Abstract
The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochemical properties are described. This medicinal chemistry effort led to the identification of 1 (AMG319), a compound with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.
Related Papers
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Garib N. Murshudov, A. A. Vagin, E. J. Dodson|Acta Crystallographica Section D Biological Crystallography|1997|14.8k